Molecular Intelligence in Breast Cancer Radiation Therapy

Molecular testing is an integral component of multidisciplinary management of breast cancer. Recent evidence underscores the importance of molecular assays in radiation therapy decision making. In addition to their prognostic and predictive benefits, such assays are increasingly utilized for escalation or de-escalation of radiation therapy. This activity reviews emerging evidence supporting the use of molecular tests in early stage in-situ and invasive breast cancer. Current and future clinical trials on the topic are presented.

Topics:

  1. Molecular Testing in DCIS: Implications for Radiation Therapy
    Eileen P. Connolly, MD, PhD
  2. Genomic Profiling in Early Stage Breast Cancer: Implications for Radiation Therapy
    Corey Speers, MD, PhD
  3. Integrating Molecular Intelligence in Breast Cancer Radiation Therapy: Future Perspectives and Pipeline Trials
    Atif J. Khan, MD, MS
  4. Q and A/Case Discussions
    Youssef Zeidan, MD, PhD - Moderator
    Full Panel

This activity is available from November 19, 2025, through 11:59 p.m. Eastern time on November 18, 2027. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, radiation biologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the utility of molecular tests in radiotherapy decision making.
  • Discuss the prognostic and predictive impact of molecular tests in early-stage breast cancer.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
11/19/2025
Course expires: 
11/18/2027
Cost:
$149.00
Rating: 
0
  • Youssef Zeidan, MD, PhD, is employed by Florida International University/Baptist Health South Florida.   
  • Eileen P. Connolly, MD, PhD, is employed by Columbia University Irving Medical Center. Dr. Connolly receives grant/research funding from Eisai and Merck. 
  • Corey Speers, MD, PhD, is employed by University of Alabama Birmingham. Dr. Speers receives compensation/payment as a consultant for Exact Sciences. 
  • Atif J. Khan, MD, MS, is employed by Memorial Sloan Kettering Cancer Center. Dr. Khan receives grant/research funding from Merck and Varian. Dr. Khan owns stock in Novavax and Xtrava, Inc. Dr. Khan is a patent holder/copyright owner with Rutgers University.  

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until November 18, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.